Literature DB >> 11455503

Surveillance of bacterial resistance among isolates in Shanghai in 1999.

F Wang1, D M Zhu, F P Hu, Y Y Zhang.   

Abstract

We report here surveillance data on the bacterial resistance of clinical isolates from 11 Shanghai hospitals in 1999, for guidance in the clinical use of antibacterial agents. Of the 14,855 strains collected, 5130 (34.5%) were Gram-positive cocci and 9725 (65.5%) were Gram-negative bacilli. The most common organisms in descending order of frequency, were: Escherichia coli (16%), coagulase-negative staphylococci (CNS; 14.3%), Klebsiella spp. (12.3%), Staphylococcus aureus (11.5%), Pseudomonas aeruginosa (9.2%), Acinetobacter spp. (8.1%), and Enterococcus spp. (6.6%). Methicillin-resistant strains accounted for 64% and 77% of S. aureus and CNS, respectively. The methicillin-sensitive strains were susceptible to most agents tested, while most methicillin-resistant strains were resistant to these agents. No vancomycin-resistant staphylococci were identified. Vancomycin-resistant strains accounted for 3.6% of Enterococcus fecalis and 1.7% of E. fecium. E. coli strains resistant to piperacillin, gentamicin, and fluoroquinolones accounted for 50% or more of the strains, and the resistance rates of Klebsiella spp., Enterobacter spp., Citrobacter spp., and Acinetobacter spp. to third-generation cephalosporins had increased markedly compared with rates in recent years. Resistance rates of P. aeruginosa to ceftazidime and imipenem (27% and 20%, respectively) had also increased compared with rates in recent years. A national strategy on the limited and prudent use of antibiotics is urgently needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455503     DOI: 10.1007/s101560100019

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  8 in total

Review 1.  Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.

Authors:  H Jiang; R-N Tang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-10       Impact factor: 3.267

2.  Emergence of and risk factors for ciprofloxacin-gentamicin-resistant Escherichia coli urinary tract infections in a region of Quebec.

Authors:  Jacques Pépin; Mireille Plamondon; Caroline Lacroix; Isabelle Alarie
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.

Authors:  Yan Wang; Yamin Zou; Jiao Xie; Taotao Wang; Xiaowei Zheng; Hairong He; Weihua Dong; Jianfeng Xing; Yalin Dong
Journal:  Eur J Clin Pharmacol       Date:  2014-10-30       Impact factor: 2.953

4.  Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China.

Authors:  Minggui Wang; John H Tran; George A Jacoby; Yingyuan Zhang; Fu Wang; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  Rational antibiotic use in China: lessons learnt through introducing surgeons to Australian guidelines.

Authors:  Yan Zhang; Ken Harvey
Journal:  Aust New Zealand Health Policy       Date:  2006-05-30

Review 6.  Antibiotic resistance amongst healthcare-associated pathogens in China.

Authors:  Saber Yezli; Han Li
Journal:  Int J Antimicrob Agents       Date:  2012-09-20       Impact factor: 5.283

7.  The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections.

Authors:  Jinjian Fu; Xiaohua Ye; Cha Chen; Sidong Chen
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

8.  Burden of bacterial upper respiratory tract pathogens in school children of Nepal.

Authors:  Sangita Thapa; Shishir Gokhale; Annavarapu Laxminarasimha Sharma; Lokendra Bahadur Sapkota; Shamshul Ansari; Rajendra Gautam; Sony Shrestha; Puja Neopane
Journal:  BMJ Open Respir Res       Date:  2017-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.